著者
山本 勇樹 森元 慶三 北村 諭思 米谷 智樹 古川 壮彦
出版者
一般社団法人日本医療薬学会
雑誌
医療薬学 (ISSN:1346342X)
巻号頁・発行日
vol.37, no.10, pp.567-571, 2011 (Released:2012-10-11)
参考文献数
12

The hepatitis B virus (HBV) is a serious concern for people at high risk of exposure to blood in their work because it is very infectious. While infection can be prevented by acquiring antibodies from hepatitis B vaccine, there are low responders and non-responders to the vaccine.We examined 2 possible methods of overcoming this problem: performing an additional vaccination with a different type of vaccine and carrying out 2 additional vaccinations at monthly intervals. Regarding the former method, an additional vaccination with a different vaccine type was carried out for a subject who could acquire no antibodies after undergoing 2 series of 6 vaccinations and who had not had any antibodies to hepatitis B for about 10 years. One month later, the passive hemagglutination test (PHA test) showed that the subject had obtained a 512-fold increase in the number of antibodies. As for the latter method, 3 of 5 non-responders acquired antibodies. Also, 5 of 6 subjects who were less responsive to the vaccine acquired antibodies and maintained them for at least 3 years.We intend to improve immunization coverage by using the methods examined in this study.

言及状況

外部データベース (DOI)

Yahoo!知恵袋 (1 users, 1 posts)

新型コロナワクチンは接種者の5~10%は抗体ができません (パーセンテージは報告により異なる)。 統計的に 「年配、男、酒好き、免疫抑制剤・副腎皮質ステロイド内服あり」 人は抗体ができにくく、できても少量になることが確認されています。 で、その機序は免疫応答が低いという曖昧な言い方しかできません。 さて、 肝炎ウイルスワクチンでは、抗体ができない場合(その確率は 奇しくも新型コロナワクチンと同 ...

収集済み URL リスト